AMY-A
Long-acting amylin analog class agonist studied alongside incretin-receptor agonists in metabolic-pathway research.
Long-acting amylin analog class agonist studied alongside incretin-receptor agonists in metabolic-pathway research.
The primary literature on this compound includes Class-level amylin pharmacology reviews. Lutz, Physiol Behav (2010). Trevaskis et al., Endocrinology (2010). The references below link directly to the published record.
Every lot is synthesized in the USA, verified by HPLC, and ships with its Certificate of Analysis. It is supplied strictly for laboratory research use.
Research use only. Everything on this page describes laboratory research. This compound is supplied strictly for in-vitro research use; it is not approved by the FDA for human or veterinary use, and nothing here is a protocol or a recommendation.
Published research
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a phase 1b trialEnebo LB, et al. Lancet. 2021.PubMed →